WO1999063050A2 - Method for preparation and in vivo administration of antigen presenting cell composition - Google Patents
Method for preparation and in vivo administration of antigen presenting cell composition Download PDFInfo
- Publication number
- WO1999063050A2 WO1999063050A2 PCT/US1999/012142 US9912142W WO9963050A2 WO 1999063050 A2 WO1999063050 A2 WO 1999063050A2 US 9912142 W US9912142 W US 9912142W WO 9963050 A2 WO9963050 A2 WO 9963050A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- antigen
- cell
- patient
- effective
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 20
- 238000001727 in vivo Methods 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 178
- 239000002243 precursor Substances 0.000 claims abstract description 48
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 47
- 210000000130 stem cell Anatomy 0.000 claims abstract description 32
- 238000012258 culturing Methods 0.000 claims abstract description 23
- 238000005119 centrifugation Methods 0.000 claims abstract description 19
- 210000000601 blood cell Anatomy 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 238000003306 harvesting Methods 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims description 99
- 102000036639 antigens Human genes 0.000 claims description 99
- 239000000427 antigen Substances 0.000 claims description 97
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000009169 immunotherapy Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 230000000735 allogeneic effect Effects 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 102000036693 Thrombopoietin Human genes 0.000 claims description 4
- 108010041111 Thrombopoietin Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims description 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 230000001483 mobilizing effect Effects 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 6
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 16
- 230000016507 interphase Effects 0.000 description 16
- 239000008188 pellet Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000005135 veiled cell Anatomy 0.000 description 2
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007798 limiting dilution analysis Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011856 somatic therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010038751 tax Gene Products Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
Definitions
- the present invention relates to methods for obtaining antigen-presenting cells (APC) and precursors thereof from a patient and use of such cells for therapy in the patient.
- the methods of the present invention include a multi-step therapeutic approach comprising in vivo therapy with APC, and in particular, a method of preparing a composition containing APC useful for in vivo immunotherapy and compositions comprising such APC.
- Such regimes may include one or more of: surgery, chemotherapy, x- irradiation, immunotherapy, stem cell isolation and replacement, and in vitro simulation of the total stem cell fraction or sub-fractions derived therefrom, followed by return of the stimulated cells to the patient.
- surgery chemotherapy, x- irradiation, immunotherapy, stem cell isolation and replacement, and in vitro simulation of the total stem cell fraction or sub-fractions derived therefrom, followed by return of the stimulated cells to the patient.
- DC dendritic cells
- APC antigen presenting cells
- stem cell replacement therapy following in particular, one or more of x-irradiation, chemotherapy, and immunotherapy with cytokines.
- stem cell replacement therapy generally involves collection of patient cells, stem cell isolation, and return of the stem cells to the patient.
- Various forms of cellular immunotherapy which have gained wider acceptance recently include the in vivo administration of antigen as a means to vaccinate the patient against disease or cellular therapy with cells which have been in vitro stimulated by a particular antigen and are subsequently returned to the patient.
- Vaccination with viable antigen-pulsed APCs can accommodate this clinical need.
- the invention described herein is directed to a means of collecting APCs from cancer patients and their use in immunotherapy.
- the invention includes, in one aspect, a method for obtaining antigen presenting cells from a human patient.
- the method includes; ( 1 ) treating a patient with an agent effective to mobilize stem cells from the bone marrow into the peripheral blood, (2) obtaining from the patient a blood cell fraction enriched in peripheral blood mononuclear cells, (3) subjecting the blood cell fraction to density centrifugation,(4) harvesting the cells at the interphase to obtain a cell fraction enriched in precursor antigen-presenting cells, and (5) culturing the harvested cells under conditions effective to induce cells having the morphology, phenotype, and function of dendritic cells.
- the density centrifugation step is preferably carried out by layering the product of (2) over a separation medium having a density of 1.0605 ⁇ 0.0005 gr/ml, an osmolality of 280 mOsm/kg H 2 0, and a pH of 7.4.
- the invention is based, in part, on the discovery that a separation medium such as a colloidal silica solution having a density of 1.0605 ⁇ 0.0005 gm/ml, an osmolality of 280 mOsm/kg H 2 0, and pH 7.4 effectively separates APCs or CD34 + stem cells from the majority of blood cells when apheresed blood or a bone marrow buffy coat is overlaid on the separation medium, and that this cell fraction is particularly enriched in APC.
- a separation medium such as a colloidal silica solution having a density of 1.0605 ⁇ 0.0005 gm/ml, an osmolality of 280 mOsm/kg H 2 0, and pH 7.4 effectively separates APCs or CD34 + stem cells from the majority of blood cells when apheresed blood or a bone marrow buffy coat is overlaid on the separation medium, and that this cell fraction is particularly enriched in APC.
- the agent effective to mobilize stem cells from the bone marrow into the peripheral blood is one or more chemotherapeutic agents or x-irradiation.
- the mobilization is accomplished by administering to the patient one or more chemotherapeutic agents alone or in combination with a cytokine.
- the immunotherapy and cancer therapy methods of the present invention comprise the steps of (1) obtaining a cell fraction enriched in precursor antigen-presenting cells [as described in steps (l)-(4) above], (2) either returning a portion of the fraction of cells enriched in precursor antigen presenting cells to the patient prior to culturing, or culturing the entire fraction of cells enriched in precursor antigen presenting cells under conditions effective to induce cells having the morphology, phenotype, and function of dendritic cells followed by (3) administering the exposed cells to the patient.
- the cells of the present invention may be induced to have the morphology, phenotype, and function of dendritic cells by exposing the harvested cells to an antigen precursor such as a polypeptide containing a peptide antigen or other antigen which is effective to induce in the cultured cells, or by cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- an antigen precursor such as a polypeptide containing a peptide antigen or other antigen which is effective to induce in the cultured cells, or by cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- the antigen precursor includes DNA encoding a polypeptide containing the peptide antigen or other antigen
- exposing includes introducing the DNA into the cells that have the morphology, phenotype, and function of dendritic cells.
- the invention includes a cell composition for use in immunotherapy containing a mixture of stem cells and precursor antigen presenting cells cultured under conditions effective to induce the morphology, phenotype, and function of dendritic cells of the type described above.
- the precursor APC of the present invention are further exposed to an antigen precursor effective to induce in the changed cells, cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- Figure 1 depicts the antigen presenting capability of dendritic cells derived from the interphase versus the pellet of a blood cell fraction, from a mobilized patient, enriched in peripheral blood mononuclear cells, following density centrifugation on a medium having density of 1.0605 ⁇ 0.0005 gm/ml, an osmolality of 280 mOsm/kg H20. and a pH of 7.4, harvest and culture for a time sufficient for induction to cells that have the morphology, phenotype, and function of dendritic cells.
- the results of 3H-TdR incorporation are presented following incubation of cells derived from the interphase and pellet fractions with allogeneic cells.
- Figure 2 depicts the antigen presenting capability of dendritic cells derived from the interphase versus the pellet of a blood cell fraction, from a mobilized patient, enriched in peripheral blood mononuclear cells, following density centrifugation on a medium having a density of 1.0605 ⁇ 0.0005 gm/ml, an osmolality of 280 mOsm/kg H20, and pH 7.4, harvest, and culture for a time sufficient for induction to cells that have the morphology, phenotype, and function of dendritic cells in the presence of Keyhole Limpet Hemocyanin (KLH).
- KLH Keyhole Limpet Hemocyanin
- DPC Dendritic-precursor cells
- DPC peripheral blood cells which can mature into dendritic cells under suitable conditions. DPC typically have a non-dendritic morphology and are not competent to elicit a primary immune response as antigen presenting cells.
- Dendritic cells are matured DPC, which typically have a dendritic cell morphology, that is, they are large veiled cells which extend dendrites when cultured in vitro. When pulsed with antigen or peptide, such DC are capable of presenting antigen to naive T cells.
- Precursor antigen presenting cells are cells that when exposed to an antigen or peptide are capable of becoming APC and presenting antigen to T cells.
- Antigen presenting cells are cells exposed to an antigen or peptide, can activate CD8 + cytotoxic T-lymphocytes (CTL) or CD4 T helper T-lymphocytes in an immune response.
- CTL cytotoxic T-lymphocytes
- CD4 T helper T-lymphocytes in an immune response.
- Transplantation of bone marrow and peripheral blood is performed in the clinic for the treatment of cancer and hematopoietic disorders.
- the bone marrow and peripheral blood products are processed before being reinfused in the patients.
- a patient may be treated with one or more chemotherapeutic agents or by x-irradiation as a part of the treatment regime for cancer therapy.
- Such treatment regimes have been demonstrated to result in mobilization of stem cells. [Heinzinger et al., Leukemia (ENGLAND) 12 (3) p333-9, (1998)].
- Such mobilization may also be accomplished by other means including, but not limited to. administering to the patient one or more chemotherapeutic agents, which may or may not be followed by administration of a cytokine.
- Other treatment regimes may involve cytokine administration alone.
- Methods of administration of the therapeutic agent or cvtokines of the present invention may include, but are not limited to, intravenous (IV) infusion through a central venous catheter, subcutaneous (SC) injection, oral, intranasal, transdermal, intraperitoneal (IP), intramuscular (IM), or intrapulmonary administration.
- IV intravenous
- SC subcutaneous
- IP intraperitoneal
- IM intramuscular
- Preferred chemotherapeutic agents for mobilization include, but are not limited to, one or more of, cyclophosphamide, etoposide or carmustine.
- Other chemotherapeutic agents include those commonly used in the relevant art. [Moskowitz et al., Clin. Cancer Res., 4(2)31 1-6, (1998)].
- cytokines for mobilization include, but are not limited to, one or more of, granulocyte colony stimulating factor (GCSF) or granulocyte macrophage colony stimulating factor (GMCSF), stem-cell factor (SCF), fetal liver kinase-3 protein ligand (FLT3-L), interleukin 3 (IL-3), and thrombopoietin.
- Cytokines may also be administered to the patient in the form of fusion proteins.
- the fraction of stem cells obtained from patients that have been treated by one or more of chemotherapy, x- irradiation and therapy with cytokines is enriched in precursor APC that can be isolated by the methods of the present invention, as set forth below.
- a fraction enriched in APC may be obtained by (1 ) obtaining, from a human blood sample, a monocyte-depleted cell fraction containing peripheral blood lymphocytes and dendritic-precursor cells, (2) enriching the portion of dendritic cells in the harvested cells by density centrifugation, to obtain a fraction enriched in APC, (3) culturing the cell fraction in a serum-free medium for a period sufficient to produce a morphological and biological change in dendritic-precursor cells to cells having the morphology and function of dendritic cells, and (4) harvesting non-adherent cells produced by the culturing.
- any tubes suitable for use in centrifugation may be used for the practice of the invention.
- the exemplified method achieves step (2) by density centrifugation, as detailed below, it will be understood that other approaches may be used to obtain such a monocyte-depleted cell fraction.
- counterflow elutriation centrifugation [Kabel, P.J., et al., Immunobiology
- 179:395-41 (1989)] may be employed to enrich for dendritic cells.
- apheresed blood from a cancer patient previously treated with G-CSF is directly loaded into a cell-trap centrifugation tube containing, e.g., a colloidal silica solution filled to a level above the constriction, which solution has been adjusted to the preferred density of 1.0605 ⁇
- the density of the gradient solution may be adjusted on a densitometer to precisely define its accuracy up to at least the fourth decimal place.
- gradient materials may be used to achieve progenitor cell enrichment, and they include, but are not limited to, "FICOLL”. "FICOLL-ITYPAQUE", cesium chloride. "PERCOLL” and equivalent colloidal silica solutions, any protein solution such as albumin and any sugar solution such as sucrose and dextran.
- the density gradient solution should be prepared and adjusted to the appropriate density, osmolality and pH according to that disclosed herein, prior to its use.
- the gradient solution should be added to a centrifugation tube in a volume sufficient to allow all the cells having a higher density to pass through the gradient during centrifugation.
- any tubes suitable for use in centrifugation may be used for the practice of the invention. It is preferred that a cell-trap tube which contains within it a constriction or a trap and a properly adjusted density gradient material for the density separation of CD34" cells be used in the centrifugation step of the present invention. (Van Vlasselaer, U. S. Pat No. 5,474, 687).
- the present invention is based on the finding that the fraction present at the interphase following density centrifugation is enriched in DC, antigen presenting cells and precursors thereof. Accordingly, isolation of APC is dependent on the separation characte ⁇ stics of the density gradient used, which in turn depends on the physical attributes such as the density, osmola ⁇ ty and pH of the gradient material used It will be appreciated that any separation medium having a combination of these characte ⁇ stics such as presented above, is effective for obtaining a cell fraction enriched for APC and precursors thereof
- the purity of DC in this fraction may be quantified using, for example, flow cytometry cell sorting (FACS) analysis, together with functional assays
- the cells are incubated with 10 L of an antibody and the DNA dye
- the separated cells from one or more of the interphase and pellet are harvested, washed, and resuspended in a suitable culture medium, inoculated into tissue culture vessels and cultured in a humidified incubator for at least 24 hours, preferably about 40 hours
- the culturing penod is sufficiently-long to produce a morphological and functional change in the dendritic-precursor cells
- DPC dendritic cells
- This morphological change may be detected using, for example, photomicroscopy DC are large sized veiled cells which, when cultured in vitro, typically extend cytoplasmic processes from the cell surface
- the culture medium used in the DC isolation procedure, and particularly in the culturing step desc ⁇ bed in the above paragraph is preferably serum-free
- Serum-free media which resulted in improved purity of subsequently-harvested DC cells included DMEM/F-12, Enriched Monocyte SFM, AIM-V and Enriched AIM-V All of these are available from Gibco/BRL Life Technologies, Gaithersburg, MD Other serum-free media may also be employed in the practice of the present invention Examples include Hyb ⁇ doma Serum-Free Medium (Gibco), Protein-Free Hyb ⁇ doma Medium (Gibco), Iscove's Modified Dulbecco's Medium (IMDM, Sigma), and MCBD medium (Sigma) If additional purification is desired, the cell fraction enriched in DC, antigen presenting cells and precursors thereof may be subjected to additional purification steps.
- antibodies directed against various antigens not expressed on DC may be immobilized on a solid support and used to remove, or "negatively deplete", contaminating cells. Such additional purification can result in further enrichment of DC cells, without appreciable loss of APC.
- APC in the fraction have the characteristics of the DC cells stated above, as well as the ability to stimulate a primary immune response mediated by MHC class I restricted CTL. This functional competence is assessed by measuring the proliferative response in an allogeneic T-cell stimulation setting as detected by tritiated thymidine incorporation.
- a further characteristic of APC is the ability to activate naive CD8" cytotoxic T-lymphocytes
- CTL in a primary immune response, after being pulsed with an antigen.
- the degree of enrichment of APC in the final fraction may be determined using, for example, limiting dilution analysis in a
- CTL-activating assay by mixing serial dilutions of allogeneic cells with a selected cell fraction and evaluating the expansion of T-cells, e.g., as detailed in Example II.
- the relative ability of the cells to present antigen in association with an MHC and capable of activating T-cells can be estimated based on the relative extent of cell proliferation following such stimulation.
- True antigen presenting cells can activate naive CD8 T cytotoxic T-lymphocytes (CTL) in a primary immune response, after being pulsed with an antigen.
- CTL cytotoxic T-lymphocytes
- KLH an antigen not normally encountered by such cells may be employed by those of skill in the art to determine the ability of APC to activate naive T cells.
- the respective ability of each cell fraction to present antigen in association with MHC and activate T- cells may be estimated based on the relative extent of cell proliferation following such stimulation.
- fractionated cells are either ( 1 ) cultured for 40 hours, then mixed with allogeneic "stimulators” or cells derived from buffy coats that had received 3000 rads of irradiation, or (2) cultured for 40 hours in the presence of Keyhole Limpet Hemocyanin (KLH) and then mixed with allogeneic "stimulators” or cells derived from buffy coats that had received 3000 rads, in order to evaluate the ability of the cells to generate an allogeneic response or to present antigen to naive T cells, respectively.
- KLH Keyhole Limpet Hemocyanin
- the cells of the present invention may be induced to have the morphology, phenotype, and function of dendritic cells by exposing the harvested cells to an antigen precursor such as a polypeptide comprising a peptide antigen or antigen(s) which is effective to induce in the cultured cells, cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- an antigen precursor such as a polypeptide comprising a peptide antigen or antigen(s) which is effective to induce in the cultured cells, cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- APC such that the proteins are processed through the MHC class I, as opposed to class II, pathway (see, for example, Mehta-Damani, et al).
- the incorporation of antigens into liposomes has been used to accomplish such targeting [e.g..Nair, S., et al., J. Immunol. Meth. 152:237 (1992),
- Selected antigens can be introduced to APC by transfecting the cells with expression vectors containing genes encoding such antigens.
- DNA encoding a polypeptide containing the peptide antigen or other antigen, and exposing includes introducing said DNA into the morphologically changed cells.
- Transfection of APC with a gene encoding a desired antigen is an effective way to express the antigen in association with the class I MHC. Any of a variety of known methods [for example, Ausubel, F. M., et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. John Wiley and Sons, Inc., Media PA.. Mulligan, R.C.
- the antigen may be any antigen against which it is desired to mount an immune response, such as a cancer-specific or viral antigen.
- the density gradient/affinity cell separation method employed in the isolation of precursor APC may be used in a simple, closed device or kit.
- the APC or precursor thereof, isolated using the methods of the present invention may be used in a number of applications.
- the de ree of enrichment of APC in a cell fraction may be determined by measuring, for example, functional competence as assessed by the generation of peptide-specific CTL.
- the antigen presenting cell-enriched fraction is pulsed with an antigen, and serial dilutions of the pulsed fraction are made. The dilutions are then used to stimulate expansion of T-cells.
- the relative number of APC expressing the antigen in association with an MHC and capable of activating T-cells can be estimated based on the most diluted sample that results in T-cell expansion.
- Antigen-specific cytotoxic T-lymphocytes are elicited essentially as described by Mehta- Damani, et al, 1994.
- three HLA-A *0201 binding peptides may be used to elicit antigen-specific cytotoxic T-lymphocytes (CTL).
- CTL antigen-specific cytotoxic T-lymphocytes
- the first may correspond to amino acids 11-19 of the Tax gene product of human trophic leukemic virus 1 (HTLV-1; Elovaara, I., et al, J. Exp. Med. 177: 1567-1573 (1993); Kannagi, M., et al, J. Virol. 66:2928-2933 (1992); Zweerink, H.J., et al, J. Immunol.
- the second may correspond to amino acids 27-35 of the MART-1 antigen expressed on melanoma cells (Stevens, et al.) and the third may correspond to amino acids 464-472 of human immunodeficiency virus (HIV) reverse transcriptase in the polymerase gene. All peptides may be synthesized by Bachem Laboratories (Torrance, CA).
- Stock solutions are prepared by dissolving the peptides in sterile filtered 1.0% acetic acid solution in LAL water (BioWhittaker. Walkersville, MD) at a concentration of about 1 g/ml.
- the isolated DC enriched cell fraction is resuspended in 1.0 mL of basal RPMI-1640 and incubated with 1 to 5 g/mL ⁇ 2-microglobulin (Sigma Chemical Company, St. Louis, MO) and 1 to 5 g/mL peptide at 37°C for 1-2 hours.
- peptide-pulsed DC are washed to remove excess peptide and mixed with autologous T-lymphocytes (14.5% metrizamide pellet cells) at a ratio of approximately 10: 1 to yield a cell concentration of 1.0 x 10 6 cells/mL in AB Culture Medium supplemented with 4.0 U/mL of human recombinant IL-2 (Gibco Laboratories, Grand Island, NY). After 3 days of culture the IL-2 concentration is increased to 20.0 U/mL.
- the T-lymphocytes are restimulated on a weekly schedule using autologous peptide-pulsed monocytes at a ratio of 10: 1.
- the IL-2 concentration is decreased to 4.0 U/mL and is subsequently increased to 20.0 U/mL after 3 days of culture following each restimulation.
- CTL cultures are typically expanded for 3-4 weeks before evaluation of antigen-specific target cell lysis.
- FACS analysis may be done using a FACSScan flow cytometer (Becton Dickinson, San Jose, CA) connected to a Hewlett-Packard HP-9000 computer (Hewlett-Packard, Palo Alto, CA) running "LYSIS II" software (Becton Dickinson).
- the monoclonal antibodies used for analysis and their respective isotype controls may be purchased from Becton Dickinson. Briefly, approximately 100,000 cells are preincubated in each well of a 96-well plate with 50 ⁇ of rabbit serum (Sigma Chemical Company, St. Louis, MO) in a final volume of 150 ⁇ L for 15-20 minutes at room temperature to block non-specific sites for antibody binding.
- LDS-751 fluoresces in the far-red spectrum (PerCP region-detected by FL3 fluorescence channel on the FACScan) and counterstains cells, allowing for distinction between non- nucleated cell (non-staining), nucleated viable cell (weakly staining) and nucleated non-viable cell (very bright staining) populations.
- cells from two different buffy coats are mixed in a flat bottom 96 well multiwell plate at 10 5 cells of each.
- One of the buffy coats is treated with 3000 rad of irradiation and referred to as the "stimulators”.
- the other buffy coat is untreated and referred to as "responders.” If there are differences in the MHC genes of the two individuals, the cells will proliferate over a period of from about 4 to 7 days.
- Unfractionated apheresed peripheral blood products (APBL) or cells from the different density fractions are added to these co-cultures at lO 5 cells per well. These cells, referred to as “suppressors”, are treated with 1500 rad prior to being added to the MLR.
- APBL apheresed peripheral blood products
- the cells are cultured for 5 days, then pulsed with [ 3 H]-thymidine (1 Ci/well). 18 hours later, the cells are harvested and the amount of thymidine incorporated is determined in a scintillation counter. The percent suppression induced by the suppressor cells is determined by the formula:
- One of the useful features of the APC isolated by the methods of the present invention is that they are able to present antigens for the induction of primary T-cell responses.
- the APC are universally-useful antigen-presenting cells and can be employed in a wide range of immunotherapeutic, immunoprophyiactic and cancer therapeutic applications involving generation of primary and secondary immune responses.
- Cells or cell membranes can be used, for example, in direct in vivo administration, ex vivo somatic therapy, in vivo implantable devices and ex vivo extracorporeal devices. They can also be employed in the screening of antigenicity and immunogenicity of peptide epitopes from tumor- and virus-specific antigens. APC treated or pulsed with appropriate antigens can be used as potent vaccine compositions, for example against pathogenic viruses or cancerous tumors. In certain cases, it may be advantageous to use cells obtained from one individual to treat a condition in a second individual (i.e., "allogeneic" cells). For example, HIV-infected individuals with
- CTL can be isolated from healthy HLA-matched individuals, such as siblings, be stimulated or primed with antigen-pulsed DC in vitro, expanded, and administered back to the HIV-infected individuals.
- the isolated cells may also be used, for example, in gene therapy applications, such as transfection of the cells so that they constitutively express desired antigens/gene products for therapeutic applications.
- Steps include obtaining a cell fraction enriched in precursor antigen- presenting cells [as described in steps above], and either returning a portion of the enriched fraction to the patient prior to culturing, or culturing the entire fraction of cells enriched in precursor antigen presenting cells under conditions effective to induce cells having the morphology, phenotype, and function of dendritic cells followed by administering the exposed cells to the patient.
- apheresed blood samples are collected from a patient treated with one or more cytokines.
- a patient is treated with, a cytokine or fusion protein thereof, such as one or more of GCSF, GMCSF, SCF, FLT3-L, IL-3, and thrombopoietin.
- the apheresed samples are subjected to fractionation on a density gradient to form a cell layer at the gradient interphase between a first and a second separation medium each having different densities morphology, phenotype, and function of dendritic cells.
- a first separation medium may have a density of 1.0605 ⁇ 0.0005 gr/ml, an osmolality of 280 mOsm/Kg H 2 0, and a pH of 7.4 and a second separation medium may have a lighter-density.
- the cells from the interphase are harvested to obtain the stem cell fraction which is enriched in precursor antigen-presenting cells as set forth in Example I.
- a fraction of the harvested cells may be immediately returned to the patient.
- all of the harvested cells are cultured under conditions effective to induce cells having the morphology, phenotype, and function of dendritic cells.
- the induction is accomplished by exposing the harvested cells to an antigen precursor such as a polypeptide containing a peptide antigen or other antigen which is effective to induce cell-surface presentation of one or more peptide antigens by the cultured cells, against which an immune response is desired, as described above.
- Antigen precursors may be DNA encoding a polypeptide comprising the peptide antigen or other antigen, and exposing may include introducing said DNA into the morphologically changed cells.
- compositions comprising precursor APC for use in immunotherapy
- the invention includes a cell composition for use in immunotherapy containing a mixture of stem cells and precursor antigen presenting cells which have been exposed to the appropriate antigens, as set forth above.
- the precursor antigen presenting cell component of such compositions are cells that have been cultured under conditions effective to induce the morphology, phenotype, and function of dendritic cells of the type described above, and which are further exposed to an antigen precursor effective to induce cell-surface presentation of one or more peptide antigens against which an immune response is desired.
- cells derived from a tumor are used to induce the dendritic cells.
- other cancer-specific antigen(s) or viral antigens are used to induce the dendritic cells.
- an APC fused to a tumor cell or virally-infected cell is used to induce the dendritic cell fraction.
- antigen precursors may be DNA encoding a cancer-specific polypeptide comprising the peptide antigen or other antigen of interest, and exposing may include introducing the DNA into the morphologically changed cells. Following in vitro induction of the dendritic cell fraction to APC, the exposed cells comprise a pharmaceutical composition that may be administered to the patient.
- the invention provides for a rapid and high yield procedure to enrich for APC.
- the enriched APC cell population is characterized as having the function of true APCs, namely the ability to present antigen to na ⁇ ve T cells.
- true APCs namely the ability to present antigen to na ⁇ ve T cells.
- a uniformly accepted criteria for true APCs is the functional ability to present antigen to naive T cells.
- the methods described herein further provide a procedure for APC enrichment from a large blood volume, which enhances the use of such cells in both in vitro applications and in vivo therapy. Additionally, the procedure is rapid, convenient and cost effective. Processing of a complete sample requires no specialized instrumentation and can be performed by one person in a time frame of a few hours.
- WBC white blood cell count
- Apheresis was performed using a Cobe Spectra Cell Separator (Lakewood, Colorado) at a rate of 80 ml/min for 200 min (total volume of 16 L).
- the apheresed blood product was further fractionated by applying to an organosilanized colloidal silica density gradient material (U.S. Patent 4,927,750) adjusted to a density 1.0605 ⁇ 0.0005 gr/ml ("BDS"), with an osmolality of 280 mOsm/Kg H 2 0, and a pH of 7.4 and centrifuging for 30 minutes at 850 x g at room temperature.
- BDS organosilanized colloidal silica density gradient material
- apheresed blood obtained from a cancer patient was layered onto BDS, with a density of 1.0605 ⁇ 0.0005 gr/ml, an osmolality of 280 mOsm/Kg H 2 0, and a pH of 7.4, then centrifuged, as described above.
- the cells lodged at the interphase of the gradient and the cells in the pellet were evaluated for their respective ability to present antigen.
- the cells from the interphase of the gradient and the pellet were separately cultured for 40 hours and then mixed with allogeneic "stimulators" or cells derived from buffy coats that had received 3000 rads of irradiation.
- Cells were prepared as described in "A" above. The cells were cultured for 40 hours in the presence of 10 g/ml Keyhole Limpet Hemocyanin (KLH) and then mixed with allogeneic "stimulators" or cells derived from buffy coats that had received 3000 rads. 10 5 cells derived from either of the interphase, or pellet fraction, respectively, were mixed in flat bottom 96 well multiwell plates at with various numbers of stimulators per well in triplicate. 18 hours later, the cells were harvested and the amount of thymidine incorporated determined in a scintillation counter.
- KLH Keyhole Limpet Hemocyanin
- the invention described herein represents a novel method which provides the combination of mobilized APCs and precursors thereof, together with a method for enrichment of an APC population having the function of APCs, commonly accepted as the definitive characterization of the APCs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU42269/99A AU4226999A (en) | 1998-06-02 | 1999-06-01 | Method for preparation and (in vivo) administration of antigen presenting cell composition |
EP99926111A EP1082411A2 (en) | 1998-06-02 | 1999-06-01 | Method for preparation and in vivo administration of antigen presenting cell composition |
NZ508936A NZ508936A (en) | 1998-06-02 | 1999-06-01 | Method for preparation and in vivo administration of antigen presenting cell composition |
CA002330027A CA2330027A1 (en) | 1998-06-02 | 1999-06-01 | Method for preparation and in vivo administration of antigen presenting cell composition |
JP2000552246A JP2002517409A (en) | 1998-06-02 | 1999-06-01 | Preparation of antigen presenting cell compositions and methods for in vivo administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8776498P | 1998-06-02 | 1998-06-02 | |
US60/087,764 | 1998-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999063050A2 true WO1999063050A2 (en) | 1999-12-09 |
WO1999063050A3 WO1999063050A3 (en) | 2000-01-27 |
Family
ID=22207115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/012142 WO1999063050A2 (en) | 1998-06-02 | 1999-06-01 | Method for preparation and in vivo administration of antigen presenting cell composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1082411A2 (en) |
JP (1) | JP2002517409A (en) |
AU (1) | AU4226999A (en) |
CA (1) | CA2330027A1 (en) |
NZ (1) | NZ508936A (en) |
WO (1) | WO1999063050A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440735B1 (en) | 1998-03-31 | 2002-08-27 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
WO2022010847A1 (en) | 2020-07-07 | 2022-01-13 | Cancure, Llc | Mic antibodies and binding agents and methods of using the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028479A1 (en) * | 1994-04-14 | 1995-10-26 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Process for producing dendritic cells, cells thus produced and container for carrying out this process |
US5474687A (en) * | 1994-08-31 | 1995-12-12 | Activated Cell Therapy, Inc. | Methods for enriching CD34+ human hematopoietic progenitor cells |
WO1995034638A1 (en) * | 1994-06-14 | 1995-12-21 | The Board Of Trustees Of Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
WO1997003186A2 (en) * | 1995-07-12 | 1997-01-30 | Activated Cell Therapy, Inc. | Method for in vitro proliferation of dentritic cells, composition containing the cells entrapped in a three-dimensional matrix and use for immunization |
-
1999
- 1999-06-01 NZ NZ508936A patent/NZ508936A/en unknown
- 1999-06-01 CA CA002330027A patent/CA2330027A1/en not_active Abandoned
- 1999-06-01 EP EP99926111A patent/EP1082411A2/en not_active Withdrawn
- 1999-06-01 JP JP2000552246A patent/JP2002517409A/en not_active Withdrawn
- 1999-06-01 AU AU42269/99A patent/AU4226999A/en not_active Abandoned
- 1999-06-01 WO PCT/US1999/012142 patent/WO1999063050A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028479A1 (en) * | 1994-04-14 | 1995-10-26 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Process for producing dendritic cells, cells thus produced and container for carrying out this process |
WO1995034638A1 (en) * | 1994-06-14 | 1995-12-21 | The Board Of Trustees Of Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
US5474687A (en) * | 1994-08-31 | 1995-12-12 | Activated Cell Therapy, Inc. | Methods for enriching CD34+ human hematopoietic progenitor cells |
WO1997003186A2 (en) * | 1995-07-12 | 1997-01-30 | Activated Cell Therapy, Inc. | Method for in vitro proliferation of dentritic cells, composition containing the cells entrapped in a three-dimensional matrix and use for immunization |
Non-Patent Citations (2)
Title |
---|
HSU F J ET AL: "VACCINATION OF PATIENTS WITH B-CELL LYMPHOMA USING AUTOLOGOUS ANTIGEN-PULSED DENTRITIC CELLS" NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 2, no. 1, January 1996 (1996-01), page 52-58 XP000605401 ISSN: 1078-8956 * |
SIENA S ET AL: "MASSIVE EX VIVO GENERATION OF FUNCTIONAL DENDRITIC CELLS FROM MOBILIZED CD34+ BLOOD PROGENITORS FOR ANTICANCER THERAPY" EXPERIMENTAL HEMATOLOGY,US,NEW YORK, NY, vol. 23, no. 14, 1995, page 1463-1471 XP000198738 ISSN: 0301-472X * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440735B1 (en) | 1998-03-31 | 2002-08-27 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
US7824849B2 (en) | 1998-03-31 | 2010-11-02 | Geron Corporation | Cellular telomerase vaccine and its use for treating cancer |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
US8183039B2 (en) | 1999-11-15 | 2012-05-22 | Miltenyi Biotec Gmbh | Method for isolating BDCA-4+ dendritic cells |
US10407486B2 (en) | 1999-11-15 | 2019-09-10 | Miltenyi Biotech Gmbh | Ligating BDCA-2 protein with BDCA-2 specific antibody for detecting or modulating dendritic cells |
WO2022010847A1 (en) | 2020-07-07 | 2022-01-13 | Cancure, Llc | Mic antibodies and binding agents and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
WO1999063050A3 (en) | 2000-01-27 |
NZ508936A (en) | 2005-01-28 |
EP1082411A2 (en) | 2001-03-14 |
AU4226999A (en) | 1999-12-20 |
JP2002517409A (en) | 2002-06-18 |
CA2330027A1 (en) | 1999-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smit et al. | Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells | |
US7378277B2 (en) | Methods and compositions for transforming dendritic cells and activating T cells | |
KR20210013327A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
JP2004512030A (en) | Compositions and methods for inducing a specific cytolytic T cell response | |
AU730537B2 (en) | Methods and compositions for transforming dendritic cells and activating T cells | |
EP3786288A1 (en) | Method for expanding human dc cell, and human dc cell resource library | |
JP2018531022A6 (en) | Methods for generating modified human primary blood dendritic cell lines | |
JP2018531022A (en) | Methods for generating modified human primary blood dendritic cell lines | |
US6121044A (en) | Potent antigen presenting cell composition | |
CN110713977B (en) | Culture amplification method of CD8T cells | |
EP1224262A2 (en) | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells | |
AU2018366011A1 (en) | Methods and uses for dendritic cell therapy | |
EP1082411A2 (en) | Method for preparation and in vivo administration of antigen presenting cell composition | |
US20070128670A1 (en) | Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof | |
EP0765398B1 (en) | Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using | |
AU2003220722A1 (en) | Method for preparation and in vivo administration of antigen presenting cell composition | |
Markowicz et al. | Nonviral transfection of human umbilical cord blood dendritic cells is feasible, but the yield of dendritic cells with transgene expression limits the application of this method in cancer immunotherapy | |
Burgoyne | Improved dendritic cell therapy for cancer by enhancing in vivo lymph node migration using a novel chemokine-based sorting method | |
Peshwa et al. | Potent antigen presenting cell composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2330027 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 552246 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 42269/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508936 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999926111 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999926111 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999926111 Country of ref document: EP |